Common questions about BSH (FAQ)
Q: How long after starting BSH can a person expect to notice an effect?
A: Clinical studies indicate that a reduction in reported pain was often noted within one hour of applying the medication. The timing for the full therapeutic effect of reduced inflammation may vary among individuals and may require a period of continuous treatment as prescribed.
Q: Are the side effects of BSH temporary?
A: Many of the common side effects, such as a mild burning or stinging sensation upon application, are described as being temporary in nature. Regulatory warnings mention less common but more serious ocular adverse events which may necessitate immediate discontinuation of the medicine.
Q: What are the most common reported side effects of BSH?
A: The most frequently reported effects are generally related to the eye itself, including eye pain, blurred vision, or a foreign body sensation. Other commonly reported events documented in regulatory information include sensitivity to light (photophobia) and general headache.
Q: Does BSH interact with common over-the-counter pain medications?
A: Common over-the-counter pain relievers are not explicitly listed in the regulatory interaction documents. The prescribing information focuses on a potential increased risk for ocular bleeding when BSH is used with systemic agents that can affect blood clotting, due to the NSAID class effect.
Q: Can I take BSH if I'm already taking supplements like vitamins or herbal remedies?
A: Official documents focus primarily on drug-drug interactions and require a time separation from other topical eye solutions. The NSAID classification of BSH suggests caution may be necessary with systemic products, including certain supplements, that are known to affect blood clotting, due to the potential risk of ocular bleeding. Specific supplements are not detailed in the official prescribing information.
Q: What kinds of food or drink should be avoided when taking BSH?
A: Official regulatory documents do not list specific foods or drinks that must be avoided. This is because BSH is applied to the eye and its active ingredient has very low absorption into the bloodstream, resulting in minimal systemic exposure.
Q: Can people with kidney problems use BSH?
A: Since BSH is administered topically as an eye drop and only low levels of the active ingredient reach the bloodstream, dosage adjustment is not usually indicated for patients with impaired kidney function. However, the presence of pre-existing conditions may warrant individual monitoring.
Q: Does BSH have a generic version available?
A: Yes, regulatory listings maintained by government agencies, such as the U.S. FDA, indicate that authorized generic versions of BSH are available on the market.
Q: What happens if I miss a scheduled time for BSH?
A: Patient information generally describes the procedure for a missed dose: if the application time is missed, the usual recommendation is to apply the dose as soon as the individual remembers, or to skip the missed dose and continue the regular schedule if the next application time is approaching. Doubling the application to catch up is typically not recommended.
Q: Can BSH cause weight gain or weight loss?
A: Reports of changes in body weight are not listed among the common or uncommon adverse reactions documented in the regulatory safety information for this ophthalmic formulation.
Q: Is it normal to feel a bit sick when first starting BSH?
A: Nausea is reported as a common adverse event in clinical studies. This effect may be more noticeable when a person first begins their prescribed course of treatment.
Q: Is BSH safe for long-term use?
A: BSH is prescribed for a defined, short-term perioperative course, typically lasting up to 8 to 14 days after surgery, depending on the strength. Regulatory documents warn that use extending beyond the prescribed short-term limit post-surgery may increase the risk of serious adverse events involving the corneal surface.
Q: Can BSH affect my ability to drive or operate machinery?
A: If temporary blurred vision occurs after instillation, individuals are advised in official regulatory documents that they may need to wait until their vision has cleared before driving or operating machinery.
Q: Is BSH a controlled substance?
A: No, BSH is an ophthalmic Nonsteroidal Anti-inflammatory Drug (NSAID). Regulatory listings do not classify this medicine as a controlled substance.
Q: Do I need a special diet while using BSH?
A: Due to the low level of systemic absorption of the active ingredient, official regulatory documents do not specify any dietary requirements or restrictions for patients using this topical eye solution.
Q: Is BSH a habit-forming drug?
A: BSH is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not listed as a controlled substance. Official regulatory documents do not describe this medication as having any potential for dependence or habit-forming properties.
Q: Can men and women use BSH in the same way?
A: The regulatory documents establish the safety and effectiveness of the medication for use in the general adult patient population. Official prescribing information does not indicate differences in the recommended dosing or administration protocol based on gender.
Q: Does BSH cause stomach problems?
A: Nausea has been reported as a common side effect in clinical studies. However, general gastrointestinal issues like vomiting or diarrhea are not listed in the common adverse reaction categories for the topical eye solution.
Q: How quickly does BSH leave the body?
A: Following topical application, the active ingredient is rapidly absorbed and is reported to have a biological half-life of approximately 1.4 hours in the aqueous humor of the eye. While systemic plasma levels are very low, the effect on local eye tissues can last for up to 12 hours.
Q: Can BSH affect blood pressure?
A: Reports of changes in blood pressure are not listed among the commonly or uncommonly reported adverse reactions in the regulatory safety information for the topical formulation.
Q: Do a lot of people stop taking BSH because of side effects?
A: Clinical trial summaries indicate that adverse reactions rarely resulted in discontinuation. Data indicates that the medicine has a low discontinuation rate due to adverse events during the short course of the regimen.
Q: Can I use BSH if I have an existing heart condition?
A: Official regulatory documents do not list pre-existing heart conditions as a contraindication. However, due to the NSAID class effect, caution is advised if the patient also has known bleeding tendencies or is taking other systemic medications that prolong bleeding time.
Q: Can BSH cause allergic reactions?
A: Yes, use is prohibited for individuals with a history of allergic reactions, such as asthma or hives, that were triggered by aspirin or any other NSAID. Additionally, the formulation contains sodium sulfite, which may cause severe allergic-type reactions in sensitive individuals.
Q: Does BSH have any restrictions on use before surgery?
A: The recommended dosing regimen for BSH begins one day prior to surgery. Regulatory documents suggest that applying the eye drop more than 24 hours prior to surgery may increase the potential for the occurrence and severity of certain corneal adverse events.
Q: Is BSH taken once a day or multiple times a day?
A: The medicine is generally prescribed for administration once daily (QD), with one drop instilled into the affected eye(s). It is noted that certain available strengths of the solution may require a twice-daily (BID) administration.
Q: Does BSH need to be taken with food?
A: As BSH is a topical ophthalmic solution, the official regulatory documents do not provide instructions regarding taking the drops in relation to meals. This suggests that food intake does not impact the proper use of the medication.
Q: How does BSH affect liver function?
A: Although the topical ophthalmic solution has low systemic absorption, historical research with oral formulations of the active ingredient reported isolated instances of elevated liver enzymes. These findings led to calls in research literature for continued monitoring of liver function.
Q: Is BSH a newly developed drug?
A: The active ingredient in BSH, Bromfenac, has been available for some time, with initial regulatory approval in the U.S. in 1997. The specific ophthalmic formulations and strengths have received their regulatory approvals more recently.
Q: Is there a maximum time someone can stay on BSH?
A: The official duration is a fixed, short-term regimen, typically ranging from 8 to 14 days after surgery. Regulatory warnings state that use exceeding the prescribed duration post-surgery is associated with an increased risk of serious adverse events involving the cornea.
Q: Can I use BSH if I have asthma or breathing problems?
A: Use is strictly contraindicated for individuals who have experienced allergic reactions, such as asthma, that were triggered by aspirin or other NSAIDs. The formulation also contains sodium sulfite, which is noted in regulatory warnings to have the potential to cause severe allergic-type reactions, including asthmatic episodes, in certain susceptible people.
Q: What should I do if the side effects of BSH get worse?
A: Official regulatory documents advise that if there is any evidence of corneal epithelial breakdown, such as increased pain, blurred vision, or severe eye redness, the use of BSH should be immediately stopped. Any worsening symptoms, or signs of serious adverse events, are generally communicated to a healthcare professional.
Q: Can BSH interact with natural health products I'm taking?
A: The regulatory warnings regarding the potential for increased bleeding time due to the NSAID class effect apply to systemic medications. Caution may be advised with certain natural health products that are known to affect blood clotting, though specific products are not detailed in the official prescribing information.
